This note separates what the company reported from what the evidence can support today, then defines the operating signals that should confirm or challenge the thesis.
Executive Summary
GeneDx reported second-quarter 2026 revenue of $114.4 million, an increase of 11% year over year. Whole-exome and whole-genome revenue reached $100.3 million, while associated test volume rose 32% to 30,785. The difference between revenue growth and volume growth remains an important question because the source does not disclose realized revenue per test, payer mix, or reimbursement timing.
Profitability and Liquidity
The company reported GAAP gross margin of 68.4% and company-defined adjusted gross margin of 70.4%. Adjusted net income was $0.4 million, while the GAAP net loss was $17.7 million. These figures show improving adjusted profitability but also a continuing difference between adjusted and GAAP results.
Cash, cash equivalents, marketable securities, and restricted cash totaled $133.5 million as of June 30, 2026. Long-term debt, excluding the current portion, was $96.8 million.
Research Assessment
The central research question is whether GeneDx can sustain exome and genome volume growth while improving revenue conversion and narrowing the gap between adjusted and GAAP profitability. Future reviews should monitor test mix, reimbursement, operating expenses, liquidity, and evidence of durable cash generation.
Primary Source
https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/exhibit991-q22026pressrele.htm
Disclosure
This research is provided for informational and educational purposes only. It is not personalized investment advice, an offer, a solicitation, or a recommendation to buy or sell any security.